National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, People's Republic of China.
Diabetologia. 2013 Oct;56(10):2297-307. doi: 10.1007/s00125-013-2987-9. Epub 2013 Aug 5.
AIMS/HYPOTHESIS: Decreasing mitochondrial coupling efficiency has been shown to be an effective therapy for obesity and related metabolic symptoms. Here we identified a novel mitochondrial uncoupler that promoted uncoupled respiration in a cell type-specific manner and investigated its effects on modulation of energy metabolism in vivo and in vitro.
We screened a collection of mitochondrial membrane potential depolarising compounds for a novel chemical uncoupler on isolated skeletal muscle mitochondria using a channel oxygen system. The effect on respiration of metabolic cells (L6 myotubes, 3T3-L1 adipocytes and rat primary hepatocytes) was examined and metabolic pathways sensitive to cellular ATP content were also evaluated. The chronic metabolic effects were investigated in high-fat diet-induced obese mice and standard diet-fed (SD) lean mice.
The novel uncoupler, CZ5, promoted uncoupled respiration in a cell type-specific manner. It stimulated fuel oxidation in L6 myotubes and reduced lipid accumulation in 3T3-L1 adipocytes but did not affect gluconeogenesis or the triacylglycerol content in hepatocytes. The administration of CZ5 to SD mice increased energy expenditure (EE) but did not affect body weight or adiposity. Chronic studies in mice on high-fat diet showed that CZ5 reduced body weight and improved glucose and lipid metabolism via both increased EE and suppressed energy intake. The reduced adiposity was associated with the restoration of expression of key metabolic genes in visceral adipose tissue.
CONCLUSIONS/INTERPRETATION: This work demonstrates that a cell type-specific mitochondrial chemical uncoupler may have therapeutic potential for treating high-fat diet-induced metabolic diseases.
目的/假设:降低线粒体偶联效率已被证明是治疗肥胖症和相关代谢症状的有效方法。在这里,我们鉴定了一种新型线粒体解偶联剂,它以细胞类型特异性的方式促进解偶联呼吸,并研究了其对体内和体外能量代谢调节的影响。
我们使用通道氧系统,从一组线粒体膜去极化化合物中筛选出一种新型化学解偶联剂,用于分离的骨骼肌线粒体。检测了代谢细胞(L6 肌管、3T3-L1 脂肪细胞和大鼠原代肝细胞)呼吸的变化,并评估了对细胞 ATP 含量敏感的代谢途径。在高脂肪饮食诱导的肥胖小鼠和标准饮食喂养(SD)瘦小鼠中研究了慢性代谢影响。
新型解偶联剂 CZ5 以细胞类型特异性的方式促进解偶联呼吸。它刺激 L6 肌管中的燃料氧化,并减少 3T3-L1 脂肪细胞中的脂肪堆积,但不影响肝细胞中的糖异生或三酰基甘油含量。CZ5 给药于 SD 小鼠增加能量消耗(EE),但不影响体重或肥胖。在高脂肪饮食的小鼠中进行的慢性研究表明,CZ5 通过增加 EE 和抑制能量摄入来降低体重并改善葡萄糖和脂质代谢。脂肪减少与内脏脂肪组织中关键代谢基因表达的恢复有关。
结论/解释:这项工作表明,一种细胞类型特异性线粒体化学解偶联剂可能具有治疗高脂肪饮食诱导的代谢疾病的治疗潜力。